FLT3-ITD-IN-3 

FLT3-ITD-IN-3 (13v), an orally active FLT3-ITD (FLT3 internal tandem duplication) inhibitor, disrupts FLT3 signal transduction and induced G0/G1 cell cycle arrest and apoptosis. FLT3-ITD-IN-3 (13v) is used in the research of acute myeloid leukemia (AML)^[1].

FLT3-ITD-IN-3 (13v) potently and selectively inhibits the proliferation of the three FLT3-ITD bearing cell lines MOLM-14, MOLM-13, and MV4-11, with IC₅₀ values of 0.59, 0.14 and 0.41 μM, respectively^[1].
FLT3-ITD-IN-3 (13v) strongly suppresses the phosphorylation of FLT3 and STAT5 in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

FLT3-ITD-IN-3 (13v) exhibits desirable maximum plasma concentration (C_max = 306.1 ng/mL), and moderate half-life (T_1/2 = 1.83 h)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

582.94

C₂₇H₂₁ClF₂N₆O₅

3018150-80-3

O=C(C(C(C)=C1)=NN(C2=CC(Cl)=CC=C2F)C1=O)NC3=CC=C(OC4=CC(NC(N5CC(O)C5)=O)=NC=C4)C(F)=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shengfei Wu, et al. Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)pyridine derivatives as novel FLT3-ITD inhibitors. Eur J Med Chem. 2025 May 5:289:117492.